TETRALOGIC PHARMACEUTICALS CORP 4
4 · TETRALOGIC PHARMACEUTICALS CORP · Filed Dec 19, 2013
Insider Transaction Report
Form 4
Gavin Brenda D
Director
Transactions
- Conversion
Convertible Notes
2013-12-17−48,183→ 0 total(indirect: See footnote)Exercise: $7.00→ Common Stock (48,183 underlying) - Conversion
Common Stock
2013-12-17$7.00/sh+48,183$337,281→ 948,268 total(indirect: See footnote)
Footnotes (2)
- [F1]The Convertible Notes and Accrued Interest automatically converted into Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering, at the initial public offering price of $7.00 per share, which occurred on December 17, 2013.
- [F2]These securities are owned of record by Quaker BioVentures, L.P. Quaker Partners Management L.P. is the general partner of Quaker BioVentures, L.P. The reporting person, a partner of Quaker Partners Management L.P., shares voting and investment power over the shares beneficially owned by Quaker BioVentures, L.P. and Quaker Partners Management L.P., and disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.